



06 JAN 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Satoru OI et al.

Serial No. 10/523,531

Filed February 7, 2005

:

: Confirmation No. 3706

: Mail-Stop: PCT BRANCH

: Attorney Docket No. 2005_0168A

FUSED HETEROCYCLIC COMPOUNDS
AS PEPTIDASE INHIBITORS

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A corrected filing receipt is requested in the above-referenced case. A copy of the original filing receipt is enclosed, with the changes noted thereon.

Expedited issuance of the corrected filing receipt is respectfully requested.

Respectfully submitted,

Satoru OI et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
January 6, 2006



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/523,531	02/07/2005	1614	1700	2005_0168A		23	3

CONFIRMATION NO. 3706

FILING RECEIPT



OC000000017595824

000513
 WENDEROTH, LIND & PONACK, L.L.P.
 2033 K STREET N. W.
 SUITE 800
 WASHINGTON, DC 20006-1021

Date Mailed: 12/21/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Satoru ~~Hironobu~~ OI, NARA-SHI, JAPAN;Hironobu MAEZAKI, ~~TOYONAKA-SHI~~ TOYONAKA-SHI, JAPAN

Koji IKEDOU, Himeji-shi, Japan

Power of Attorney:

Warren Cheek Jr--33367

RECEIVED
 DEC 27 2005

WENDEROTH, LIND & PONACK

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/10054 08/07/2003

Foreign Applications

JAPAN 2002-231950 08/08/2002

JAPAN 2003-51575 02/27/2003

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No

Early Publication Request: No

Title

Fused heterocyclic compounds as petidase inhibitors

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

10 Rec'd PCT/PTO 06 JAN 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :

Satoru OI et al. :

Mail Stop: PCT

Serial No. 10/523,531 :

Attorney Docket No. 2005_0168A

Filed February 7, 2005 :

Confirmation No. 3706

FUSED HETEROCYCLIC COMPOUNDS
AS PEPTIDASE INHIBITORS

[Corresponding to PCT/JP03/10054 Filed August 7, 2003]

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.**REPLY TO NOTIFICATION OF INSUFFICIENT FEES**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the Notice dated December 21, 2005. Applicants respectfully disagree that additional fees of \$850.00 are required in this application. The undersigned and his secretary Donna King have made numerous attempts to contact the person listed on the Notice but have received no return telephone calls to date.

There are a total of 23 total claims in this application. We paid for 3 additional claims exceeding 20 in the amount of \$150.00. There are 3 independent claims. The application contains 246 pages. We paid a fee of \$750.00 for exceeding the 100 page application size fee (3 x \$250.00). If the Preliminary Amendment pages are included, we owe an additional fee of \$250.00.


Enclosed please find copies of the Preliminary Amendment, Postcard and PCT Transmittal Letter filed on February 7, 2005.

The PTO is authorized to charge any deficient filing fee to the Deposit Account No. 23-0975. Reconsideration of the amount in appreciated.

Respectfully submitted,

Satoru OI et al.

By


Warren M. Check, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk

Washington, D.C. 20006-1021

Telephone (202) 721-8200

Facsimile (202) 721-8250

January 17, 2006

1-31-06

10 Rec'd PCT/PTC

06 JAN 2006

703-305-13230

Attn Mrs. Washington

Thank you!

Warren Cheele

20 Res'd PCT/PTO 06 JAN 2006

DT07 Res'd PCT/PTO 07 FEB 2005

ATTY DOCKET #: 2005_0168A

Due Date: February 7, 2005

OUR REF: 2005_0168A/WMC/00279

10/523531

Applicant: Satoru Oi et al.

Serial No.: NEW

Filing Date: February 7, 2005


Title: FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS

Receipt of the following papers is acknowledged:

1. Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 USC 371 (National stage application of PCT/JP03/10054)
2. Attachments: (A) An International Application including Specification, Claims and Abstract (246 pages), (B) Executed Declaration, (C) IDS, PTO-1449 form, 6 references, (C) Assignment Recordal Sheet, Assignment, International Search Report, International Preliminary Examination Report, (D) Preliminary Amendment.
3. Check in the amount of \$1,840.00

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 28-0275.

Date February 7, 2005



[Check No. 66489]

COPY